All In Biotech

Drug Trial Radar · NCT00304616

SWitching to Abilify Trial (SWAT)

A Multi-center, Randomized, Open, Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients

Last checked: Nov 20, 2026Latest source record: Dec 17, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Oct 2004

Primary completion

Jun 2006

Study completion Oct 2007

Sponsor

Sponsor type
Industry
First posted
Mar 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration

Conditions

  • Schizophrenia

Interventions

  • Aripiprazole, Solian, Olanzapine, Seroquel, RisperidoneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CGI-I mean score(at week 1, 3, 4, 8 & every 4 weeks until week 26)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.